Iloperidone CAS NO:133454-47-4

Product Description:

Product Name: Iloperidone CAS NO:133454-47-4

Synonyms:

1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphen yl]ethanone;

Chemical & Physical Properties:

Appearance : white to off-white powder

Assay :≥99.0%

Density:1.2g/cm3

Boiling Point:593.7℃ at 760 mmHg

Flash Point: 312.8℃

Melting Point:118-120℃

Iloperidone, an atypical antipsychotic drug, is the dual antagonist of the serotonin-2 (5-HT2) and dopamine 2 (D2). The development process of iloperidone is a bit dramatic. It is originally synthesized and identified by HE Manchester-Russell pharmaceutical companies, however, the company decided to give up further development of it, and assigned it to the Titan Pharmaceuticals; At January 1997, Titan Pharmaceuticals further transferred the goods to Novartis, and the latter one invested the III phase of the clinical development of this product and assume the registration fees of this drugs worldwide except Japan (Titan Pharmaceuticals retains the right to develop this product in Japan); however, in 2004, the Vanda Pharmaceuticals in 2004 obtain the right to develop this product from Novartis. On May 6, 2009, the US FDA approved that Vanda Pharma Company had successfully developed iloperidone (trade name: Fanapt) and make it enter into market which is mainly used for clinical treatment of adults schizophrenia.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.